ALS INVESTMENT FUND

We invest in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus in ALS.

NEURODEGENERATIVE DISEASES ARE ONE OF THE MAIN HEALTH CHALLENGES OF HUMANKIND

We all want to live longer with sound minds and strong bodies. In order to do this we must tackle the challenge of progressive diseases that destroy the neurons controlling our memories, muscles, and other areas of the body. Alzheimer’s disease, Parkinson’s disease, and ALS all result from this fundamental problem of dying neurons.

INVESTMENT PHILOSOPHY

We invest in biotech companies with strong founders applying cutting edge technologies. We look for companies with either platform approaches relevant to multiple diseases, and/or with multiple drugs already in clinical development. The companies in our portfolio have already proven the basic science behind their approaches and are working towards a value inflection point.

PORTFOLIO

AMYLYX exited

Amylyx is a commercial stage company developing proprietary therapeutics for Amyotrophic Lateral Sclerosis and other neurodegenerative diseases. ALS IF exited the company in 2023.

Learn more
ORPHAZYME exited

Orphazyme was founded in 2009 with the objective to develop new therapies for patients suffering from protein-misfolding diseases with no or limited treatment options available. ALS IF exited the company in 2022.

Learn more
EMULATE

The platform offers researchers a new standard for predicting how a human may respond to medicines, chemicals, and foods — with greater precision and control than today’s cell culture or animal-based testing methods. KIID (EID) DUTCH, KIID (EID) ENG

Learn more
VERGE GENOMICS

Verge is a clinical stage biotech company that was founded on the belief that exponential advances in computational genomics, combined with new insights in neuroscience, will lead to breakthrough opportunities to identify targets and discover drugs that can dramatically improve the lives of patients suffering from neurodegenerative diseases. KIID (EID) DUTCH, KIID (EID) ENG

Learn more
APIC BIO

Apic Bio Inc. (”Apic”) is a Boston based gene therapy company with a clinical stage program and a new, ground breaking technology platform. KIID (EID) DUTCH, KIID (EID) ENG

Learn more
PRILENIA

Prilenia is a clinical stage biotech company, founded by the former President of Global R&D and CSO of Teva, with 2 late stage programs for ALS and Huntington's disease currently in development. KIID (EID) DUTCH, KIID (EID) ENG

Learn more
QURALIS

QurAlis is a clinical stage biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases. KIID (EID) DUTCH, KIID (EID) ENG

Learn More
BLOOM SCIENCE

Bloom Science is a clinical-stage biotech company advancing a deep pipeline of programs that target the Gut-Brain axis for indications including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders. KIID (EID) DUTCH, KIID (EID) ENG

Learn more
VECTORY

We are an Amsterdam-based biotech company founded in 2020 with a mission to develop vectorized antibody treatments for people with neurodegenerative diseases, enabling longer, better lives.

Learn more

NICHE INVESTMENT WITH A BROAD REACH

We are a highly specialized biotech investor. We currently manage the largest and most diversified portfolio of ALS related companies worldwide. We are also globally among the most diversified VC funds in neurodegeneration in general with the ambition to build out this position. The knowledge we gather through our portfolio and our longstanding relationships with a global ALS-related network of scientists, clinicians, foundations, and patient advocates, differentiates us from other investors.

TEAM